All In Biotech

Drug Trial Radar · NCT05039450

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Jul 30, 2021

Primary completion

Dec 15, 2023

Study completion Aug 28, 2025

Sponsor

Lead sponsor
Akero Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Sep 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • EFXDrug

    Investigational drug, Efruxifermin

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main: Change From Baseline in Fibrosis With no Worsening Steatohepatitis Assessed by NASH CRN SystemTime frame: Week 36

Locations

49 sites in 3 countries. Site status is shown where the registry gives one.

  • Akero Clinical Study Site

    Chandler, Arizona

  • Akero Clinical Study Site

    Glendale, Arizona

  • Akero Clinical Study Site

    Tucson, Arizona

  • Akero Clinical Study Site

    Tucson, Arizona

  • Akero Clinical Study Site

    North Little Rock, Arkansas

  • Akero Clinical Study Site

    Fresno, California

  • Akero Clinical Study Site

    Long Beach, California

  • Akero Clinical Study Site

    Los Angeles, California

  • Akero Clinical Study Site

    Pasadena, California

  • Akero Clinical Study Site

    Englewood, Colorado

  • Akero Clinical Study Site

    Clearwater, Florida

  • Akero Clinical Study Site

    Fort Myers, Florida

  • Akero Clinical Study Site

    Fort Myers, Florida

  • Akero Clinical Study Site

    Hialeah Gardens, Florida

  • Akero Clinical Study Site

    Lakewood Rch, Florida

  • Akero Clinical Study Site

    Miami Lakes, Florida

  • Akero Clinical Study Site

    Ocala, Florida

  • Akero Clinical Study Site

    Sarasota, Florida

  • Akero Clinical Study Site

    South Bend, Indiana

  • Akero Clinical Study Site

    Topeka, Kansas

  • Akero Clinical Study Site

    Bastrop, Louisiana

  • Akero Clinical Study Site

    Marrero, Louisiana

  • Akero Clinical Study Site

    Las Vegas, Nevada

  • Akero Clinical Study Site

    Concord, North Carolina

  • Akero Clinical Study Site

    Fayetteville, North Carolina

  • Akero Clinical Study Site

    Morehead City, North Carolina

  • Akero Clinical Study Site

    Springboro, Ohio

  • Akero Clinical Study Site

    Westlake, Ohio

  • Akero Clinical Study Site

    Greenville, South Carolina

  • Akero Clinical Study Site

    Greenwood, South Carolina

  • Akero Clinical Study Site

    Summerville, South Carolina

  • Akero Clinical Study Site

    Nashville, Tennessee

  • Akero Clinical Study Site

    Austin, Texas

  • Akero Clinical Study Site

    Dallas, Texas

  • Akero Clinical Study Site

    Edinburg, Texas

  • Akero Clinical Study Site

    Edinburg, Texas

  • Akero Clinical Study Site

    Fort Worth, Texas

  • Akero Clinical Study Site

    Fort Worth, Texas

  • Akero Clinical Study Site

    Houston, Texas

  • Akero Clinical Study Site

    Houston, Texas

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.